Pharmacology · Anti-Seizure Drugs

Absence Seizures and Newer Agents

Ethosuximide, levetiracetam, topiramate, gabapentin, and pregabalin

Ethosuximide opens this module because it is the clinical endpoint of everything established in Module 1. T-type calcium channels in thalamic relay neurons generate the 3-Hz spike-and-wave discharge that defines absence epilepsy. Ethosuximide blocks exactly those channels and nothing else — which is why it works for pure absence and why the sodium channel blockers from Module 2 do not.
Levetiracetam's mechanism is in a category by itself: synaptic vesicle protein 2A modulation is unrelated to sodium channels, calcium channels, or gamma-aminobutyric acid receptors. That mechanistic isolation is clinically useful because it means levetiracetam has no cytochrome P450 interactions, making it one of the few anti-seizure drugs that can be added to complex regimens without requiring dose adjustments across the board.
Topiramate's adverse effects are dose-limiting in a distinct way from other agents. The cognitive impairment is common enough to have acquired a clinical nickname ("Dopamax"), and it is the reason many patients stop the drug despite good seizure control. The weight loss, by contrast, is a property that has been used therapeutically in non-epilepsy indications.
The gabapentin and pregabalin card carries a naming trap that appears regularly in pharmacology examinations. The "gaba" in the names refers to the structural resemblance to gamma-aminobutyric acid used in the original synthesis, not to the mechanism of action. Neither drug acts at gamma-aminobutyric acid receptors. Both bind the alpha-2-delta subunit of voltage-gated calcium channels.
The rule box at the bottom restates the gabapentin naming trap as an explicit examination warning. Gabapentin also worsens absence seizures — another consequence of the name being pharmacologically misleading if taken literally.

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Glauser T, Cnaan A, Shinnar S, et al.	Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy	N Engl J Med. 2010;362(9):790–799
Lynch BA, Lambeng N, Nocka K, et al.	The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam	Proc Natl Acad Sci USA. 2004;101(26):9861–9866
Taylor CP, Angelotti T, Fauman E	Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta subunit as a target for antiepileptic drug discovery	Epilepsy Res. 2007;73(2):137–150
Biton V	Clinical pharmacology and mechanism of action of zonisamide and topiramate	Clin Neuropharmacol. 2007;30(4):230–242
Le T, Bhushan V, eds.	First Aid for the USMLE Step 1 (current edition)	McGraw-Hill